Revenues

6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Revenues

Note 13. Revenues

The Company sells Sunosi and Auvelity in the United States through the Distributors. The Company sells Sunosi, on a product supply basis, to Pharmanovia, and Sunosi is subsequently sold within the licensed territories.

License revenue consists of the recognition of the upfront payment the Company received from Pharmanovia in February 2023 and royalty revenue is related to sales of Sunosi by Pharmanovia in certain ex-U.S. markets.

The following table presents a summary of total revenues by product:

	Three months ended June 30,				Six months ended June 30,
	2024		2023		2024		2023
Product sales, net
Auvelity	$	65,025	$	27,643	$	118,420	$	43,393
Sunosi		21,495		18,374		42,196		31,193
Total product sales, net		86,520		46,017		160,616		74,586
Sunosi license revenue		—		—		—		65,735
Sunosi royalty revenue		646		683		1,549		955
Total revenues	$	87,166	$	46,700	$	162,165	$	141,276

The following table presents a summary of total revenues by geographic location:

	Three months ended June 30,				Six months ended June 30,
	2024		2023		2024		2023
Product sales, net
United States	$	85,444	$	45,418	$	158,715	$	72,344
Outside of the United States		1,076		599		1,901		2,242
Total product sales, net		86,520		46,017		160,616		74,586
License revenue
Outside of the United States		—		—		—		65,735
Royalty revenue
Outside of the United States		646		683		1,549		955
Total revenues	$	87,166	$	46,700	$	162,165	$	141,276

For the six months ended June 30, 2024, product sales, net, includes adjustments for provisions for product sales made in 2023 resulting from changes in estimates of $1.1 million for Auvelity and $0.6 million for Sunosi. For the six months ended June 30, 2023, product sales, net, includes adjustments for provisions for product sales made in 2022 resulting from changes in estimates of $0.8 million for Auvelity and $0.1 million for Sunosi.